Testing a new anti-inflammatory drug for active myositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This study tests whether adding a new anti-inflammatory drug (Maraviroc) to your current treatment can better control active myositis (inflammatory muscle disease) when other treatments have not worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old
- You were first diagnosed with myositis (inflammatory muscle disease) after age 18
- You have been diagnosed with myositis using the official 2017 criteria set by rheumatology experts
- Your myositis is still active—meaning your muscle strength is low (MMT8 score under 142) and you have at least two other signs like high muscle enzymes, high disease activity on a doctor's or your own global assessment, or trouble with daily tasks
- You have already tried at least two other immunosuppressive medications (besides steroids) to control your myositis, and it's still active
- You are not pregnant or breastfeeding, have no current cancer, and have no allergy or reason you cannot take the study drug (Maraviroc)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This study is creating a group of patients with idiopathic inflammatory myositis (a condition where your immune system attacks your muscles) to better understand the disease and improve care. It's open to adults ages 18 to 75 who have been diagnosed using specific medical guidelines.
This study tests a new oral medication, nerandomilast, for people with active idiopathic inflammatory myopathies (a group of rare autoimmune diseases causing muscle weakness). It aims to see if the drug can reduce disease activity safely. Participants must have moderate-to-severe symptoms and be on standard treatments.
This trial tests an investigational drug called Telitacicept for people with inflammatory myopathies (muscle inflammation). It aims to see if the drug can help when standard treatments haven't worked well.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial is testing an investigational medicine called PF-08154225 for people with autoimmune diseases like rheumatoid arthritis, lupus, myositis, or systemic sclerosis. It aims to see if the drug is safe and effective in reducing disease activity.
Hear when a new Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.